Efficacy and safety of nasal high-flow oxygen in COPD patients.

Vogelsinger, Helene; Halank, Michael; Braun, Silke; Wilkens, Heinrike; Geiser, Thomas; Ott, Sebastian Robert; Stucki, Armin; Kaehler, Christian M (2017). Efficacy and safety of nasal high-flow oxygen in COPD patients. BMC pulmonary medicine, 17(1), p. 143. BioMed Central 10.1186/s12890-017-0486-3

[img]
Preview
Text
s12890-017-0486-3.pdf - Submitted Version
Available under License Creative Commons: Attribution (CC-BY).

Download (660kB) | Preview

BACKGROUND Nasal high-flow oxygen therapy (HFOT) is a novel treatment option for patients suffering from acute or chronic respiratory failure. Aim of our study was to compare safety and efficacy of HFOT with those of conventional oxygen treatment (COT) in normo- and hypercapnic COPD patients. METHODS A single cohort of 77 clinically stable hypoxemic patients with an indication for long-term oxygen treatment (LTOT) with or without hypercapnia successively received COT and HFOT for 60 min each, including oxygen adaption and separated by a 30 min washout phase. RESULTS HFOT was well-tolerated in all patients. A significant decrease in PaCO2 was observed during oxygen adaption of HFOT, and increased PaO2 coincided with significantly increased SpO2 and decreased AaDO2 during both treatment phases. Even at a flow rate of 15 L/min, oxygen requirement delivered as air mixture by HFOT tended to be lower than that of COT (2.2 L/min). Not only was no increase in static or dynamic lung volumes observed during HFOT, but even was a significant reduction of residual lung volume measured in 36 patients (28%). CONCLUSIONS Thus, short-term use of HFOT is safe in both normocapnic and hypercapnic COPD patients. Lower oxygen levels were effective in correcting hypoxemic respiratory failure and reducing hypercapnia, leading to a reduced amount of oxygen consumption. Long-term studies are needed to assess safety, tolerability, and clinical efficacy of HFOT. TRIAL REGISTRATION ClinicalTrials.gov NCT01686893 13.09.2012 retrospectively registered (STIT-1) and NCT01693146 14.09.2012 retrospectively registered (STIT-2). Studies were approved by the local ethics committee (Ethikkommission der Medizinischen Universität Innsbruck, Studienkennzahl UN3547, Sitzungsnummer 274/4.19).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology

UniBE Contributor:

Geiser, Thomas and Ott, Sebastian Robert

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1471-2466

Publisher:

BioMed Central

Language:

English

Submitter:

Rahel Holderegger

Date Deposited:

30 Jan 2018 16:05

Last Modified:

30 Jan 2018 16:14

Publisher DOI:

10.1186/s12890-017-0486-3

PubMed ID:

29149867

Uncontrolled Keywords:

COPD. High-flow oxygen hypercapnic. normocapnic. short-term nasal highflow.

BORIS DOI:

10.7892/boris.108532

URI:

https://boris.unibe.ch/id/eprint/108532

Actions (login required)

Edit item Edit item
Provide Feedback